WO2000056882A1 - 48 proteines humaines secretees - Google Patents

48 proteines humaines secretees Download PDF

Info

Publication number
WO2000056882A1
WO2000056882A1 PCT/US2000/006791 US0006791W WO0056882A1 WO 2000056882 A1 WO2000056882 A1 WO 2000056882A1 US 0006791 W US0006791 W US 0006791W WO 0056882 A1 WO0056882 A1 WO 0056882A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence
human
polypeptide
polynucleotide
Prior art date
Application number
PCT/US2000/006791
Other languages
English (en)
Inventor
Craig A. Rosen
Steven M. Ruben
George Komatsoulis
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00917963A priority Critical patent/EP1163332A1/fr
Priority to JP2000606741A priority patent/JP2002539786A/ja
Priority to CA002366132A priority patent/CA2366132A1/fr
Priority to AU38857/00A priority patent/AU3885700A/en
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Publication of WO2000056882A1 publication Critical patent/WO2000056882A1/fr
Priority to US10/472,965 priority patent/US20070026454A1/en
Priority to US10/105,299 priority patent/US7368527B2/en
Priority to US10/472,964 priority patent/US20070032414A1/en
Priority to US10/670,185 priority patent/US20070015162A1/en
Priority to US10/670,186 priority patent/US20070031842A1/en
Priority to US10/868,184 priority patent/US20070048818A1/en
Priority to US10/994,608 priority patent/US20070048297A1/en
Priority to US11/781,665 priority patent/US20070298491A1/en
Priority to US12/753,401 priority patent/US8410248B2/en
Priority to US13/848,789 priority patent/US20130203164A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.
  • isolated refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state.
  • an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.
  • the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 438 of SEQ ID NO: 15, b is an integer of 15 to 452, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 15, and where b is greater than or equal to a + 14.
  • Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 116 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). It has been discovered that this gene is expressed primarily in Human Fetal
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2487 of SEQ ID NO: 16, b is an integer of 15 to 2501, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO: 16, and where b is greater than or equal to a + 14.
  • Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 118 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed). It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares_multiple_sclerosis_2NbHMSP and to a lesser extent in Soares infant brain 1NIB; Spinal cord; Soares_NhHMPu_S 1 ; Heart; H. hypothalamus, frac A,re-excision; prostate-edited; Human Adult Retina; H. Atrophic Endometrium; Stratagene ovary (#937217); Human Prostate Cancer, Stage C fraction; H Female Bladder, Adult; Human Manic Depression Tissue;
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 979 of SEQ ID NO:25, b is an integer of 15 to 993, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1405 of SEQ ID NO:28, b is an integer of 15 to 1419, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 941 of SEQ ID NO:29, b is an integer of 15 to 955, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:37 Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
  • Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out as SEQ ID NO. 150 which corresponds to the Query sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).
  • the gene encoding the disclosed cDNA is believed to reside on chromosome 21. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 21.
  • polynucleotide sequences such as EST sequences
  • SEQ ID NO:55 Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome.
  • allelic variants, orthologs, and/or species homologs are also provided in the present invention. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC.
  • allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.
  • the present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).
  • Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these
  • variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification.
  • the expression vectors will preferably include at least one selectable marker.
  • markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria.
  • Representative examples of appropriate hosts include, but are not limited to. bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.
  • polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., Nature, 310: 105-111 (1984)).
  • a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer.
  • nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence.
  • multimers of the invention may be generated using genetic engineering techniques known in the art.
  • polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein inco ⁇ orated by reference in its entirety).
  • FISH fluorescence in situ hybridization
  • helper viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses.
  • packaging cells Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either ex vivo or in vivo. The transduced cells will contain the polynucleotide construct integrated into its genome, and will express the desired gene product.
  • Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g.
  • autoimmune disorders examples include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis.
  • allergic reactions and conditions such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polynucleotides or polypeptides, or agonists or antagonists of the present invention.
  • these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

L'invention porte sur de nouvelles protéines humaines sécrétées et sur des acides nucléiques isolés comportant les régions codantes des gènes codant pour lesdites protéines. L'invention porte également sur des vecteurs, cellules hôtes, anticorps, et méthodes de recombinaison servant à produire lesdites protéines humaines sécrétées; elle porte en outre sur des procédés diagnostiques et thérapeutiques permettant de diagnostiquer et traiter les affections liées auxdites nouvelles protéines humaines sécrétées.
PCT/US2000/006791 1999-03-12 2000-03-16 48 proteines humaines secretees WO2000056882A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP00917963A EP1163332A1 (fr) 1999-03-23 2000-03-16 48 proteines humaines secretees
JP2000606741A JP2002539786A (ja) 1999-03-23 2000-03-16 ４８個のヒト分泌タンパク質
CA002366132A CA2366132A1 (fr) 1999-03-23 2000-03-16 48 proteines humaines secretees
AU38857/00A AU3885700A (en) 1999-03-23 2000-03-16 48 human secreted proteins
US10/472,965 US20070026454A1 (en) 1999-03-12 2002-03-26 Human secreted proteins
US10/105,299 US7368527B2 (en) 1999-03-12 2002-03-26 HADDE71 polypeptides
US10/472,964 US20070032414A1 (en) 1999-03-12 2002-03-26 Human secreted proteins
US10/670,185 US20070015162A1 (en) 1999-03-12 2003-09-25 99 human secreted proteins
US10/670,186 US20070031842A1 (en) 1999-03-12 2003-09-25 379 human secreted proteins
US10/868,184 US20070048818A1 (en) 1999-03-12 2004-06-16 Human secreted proteins
US10/994,608 US20070048297A1 (en) 1999-03-12 2004-11-23 Human secreted proteins
US11/781,665 US20070298491A1 (en) 1999-03-12 2007-07-23 Human Secreted Proteins
US12/753,401 US8410248B2 (en) 1999-03-12 2010-04-02 HWBAO62 polypeptides
US13/848,789 US20130203164A1 (en) 1999-03-12 2013-03-22 Human Secreted Proteins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12581599P 1999-03-23 1999-03-23
US16994699P 1999-12-10 1999-12-10
US60/125,815 1999-12-10
US60/169,946 1999-12-10

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/006828 Continuation-In-Part WO2000056767A1 (fr) 1999-03-12 2000-03-16 Proteines humaines secretees (46)
PCT/US2000/006822 Continuation-In-Part WO2000056883A1 (fr) 1999-03-12 2000-03-16 49 proteines humaines secretees

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2000/006828 Continuation-In-Part WO2000056767A1 (fr) 1999-03-12 2000-03-16 Proteines humaines secretees (46)
PCT/US2000/006822 Continuation-In-Part WO2000056883A1 (fr) 1999-03-12 2000-03-16 49 proteines humaines secretees
US95008301A Continuation-In-Part 1999-03-12 2001-09-12
US95008201A Continuation-In-Part 1999-03-12 2001-09-12

Publications (1)

Publication Number Publication Date
WO2000056882A1 true WO2000056882A1 (fr) 2000-09-28

Family

ID=26823987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006791 WO2000056882A1 (fr) 1999-03-12 2000-03-16 48 proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1163332A1 (fr)
JP (1) JP2002539786A (fr)
AU (1) AU3885700A (fr)
CA (1) CA2366132A1 (fr)
WO (1) WO2000056882A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056811A1 (en) * 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof
EP2412727B1 (fr) * 2006-02-14 2016-06-29 University Of Tasmania Through The Menzies Research Institute Fragments de peptides dérivés de la métallothionéine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK ON STP 13 May 1999 (1999-05-13), TP12D07.X1 NCI CGAP GAS4 HOMO SAPIENS CDNA CLONE IMAGE:2187565 3' MRNA SEQUENCE: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index" *
DATABASE GENBANK ON STP 16 June 1998 (1998-06-16), OT73E01.S1 SOARES TOTAL FETUS NB2HF8 9W HOMO SAPIENS CDNA CLONE IMAGE: 1622424 3' MRNA SEQUENCE: "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index" *
DATABASE GENBANK ON STP 28 December 1999 (1999-12-28), XQ96108.X1 NCI. CGAP BRN53 HOMO SAPIENS CDNA CLONE IMAGE:2758503 3' MRNA SEQUENCE: "National Cancer Institute/National Institute of Neurological Disorders and Stroke, Brain Tumor Genome Anatomy Project (CGAP/BTGAP), Tumor Gene Index" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412727B1 (fr) * 2006-02-14 2016-06-29 University Of Tasmania Through The Menzies Research Institute Fragments de peptides dérivés de la métallothionéine
US20140056811A1 (en) * 2010-12-27 2014-02-27 Compugen Ltd. New cell-penetrating peptides and uses thereof

Also Published As

Publication number Publication date
EP1163332A1 (fr) 2001-12-19
AU3885700A (en) 2000-10-09
CA2366132A1 (fr) 2000-09-28
JP2002539786A (ja) 2002-11-26

Similar Documents

Publication Publication Date Title
EP1175439A1 (fr) 49 proteines humaines secretees
EP1161446A1 (fr) 50 proteines humaines secretees
EP1220947A2 (fr) 50 proteines humaines secretees
EP1173462A1 (fr) 50 proteines humaines secretees
WO2000076531A1 (fr) 47 proteines humaines secretees
WO2000055199A1 (fr) 47 proteines humaines secretees
EP1171460A1 (fr) 48 proteines secretees humaines
EP1165602A1 (fr) 49 proteines secretees par un etre humain
WO2000061596A1 (fr) 50 proteines humaines secretees
WO2000056751A1 (fr) Cinquante protéines humaines sécrétées
WO2000056753A1 (fr) 49 proteines humaines secretees
EP1163332A1 (fr) 48 proteines humaines secretees
EP1163331A1 (fr) 50 proteines humaines secretees
WO2000056883A1 (fr) 49 proteines humaines secretees
WO2000061627A1 (fr) 49 proteines secretees humaines
EP1169440A1 (fr) 48 proteines humaines secretees
WO2000056754A1 (fr) 48 proteines humaines secretees
WO2000056765A1 (fr) 48 proteines humaines secretees
WO2000061779A1 (fr) 49 proteines humaines secretees
EP1161448A1 (fr) Proteines humaines secretees (49)
WO2000061628A1 (fr) 49 proteines humaines secretees
EP1161447A1 (fr) Proteines humaines secretees (50)
WO2000058336A1 (fr) 50 proteines humaines secretees
EP1165785A1 (fr) 48 prot ines humaines secretees
WO2000055352A2 (fr) Proteines humaines secretees (50)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 606741

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000917963

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2366132

Country of ref document: CA

Ref country code: CA

Ref document number: 2366132

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000917963

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000917963

Country of ref document: EP